Tonawanda, NY, December 13, 2024—Pine Pharmaceuticals, one of the nation’s largest and most trusted FDA-registered 503B outsourcing facilities, recently announced the launch of norepinephrine 32 mg, the newest addition to its collection of ready-to-administer premix IV bags.
“We’re thrilled to offer norepinephrine as it fills a crucial gap where this specific concentration is scarcely available,” said Alfonse J. Muto, Pharm.D. “Having a product like this in our portfolio furthers our initiatives to provide facilities with the tools they need for customized patient care.”
Over the past year, Pine Pharmaceutical has steadily expanded its hospital offerings, strengthening its ability to provide critical compounds nationwide. Recent additions include diltiazem HCl, epinephrine, phenylephrine HCl, and edetate disodium 1.5%. With the introduction of norepinephrine, the company’s expanded product catalog features over 15 new products, offering more comprehensive solutions to meet critical healthcare needs.
“As we continue to expand our offerings, our ongoing mission is to provide hospitals and other providers with reliable, cost-effective solutions, in addition to reducing drug shortages nationwide,” added Muto.
About Pine Pharmaceuticals LLC
Pine Pharmaceuticals is an FDA-registered 503B outsourcing facility that specializes in the preparation of high-quality, ready-to-administer compounds and repackaged products. As a best-in-class partner, Pine Pharmaceuticals is committed to meeting the FDA’s stringent cGMP requirements while supporting hospitals, surgery centers, and practices nationwide. For more information, please visit www.pinepharmaceuticals.com or call 844-218-4138 to learn more about our products and services.
©2025 Pine Pharmaceuticals. All rights reserved.